CXCR1 and CXCR2 Inhibition by Ladarixin Improves Neutrophil-Dependent Airway Inflammation in Mice

Increased IL-8 levels and neutrophil accumulation in the airways are common features found in patients affected by pulmonary diseases such as Asthma, Idiopathic Pulmonary Fibrosis, Influenza-A infection and COPD. Chronic neutrophilic inflammation is usually corticosteroid insensitive and may be rele...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 11; p. 566953
Main Authors Mattos, Matheus Silverio, Ferrero, Maximiliano Ruben, Kraemer, Lucas, Lopes, Gabriel Augusto Oliveira, Reis, Diego Carlos, Cassali, Geovanni Dantas, Oliveira, Fabricio Marcus Silva, Brandolini, Laura, Allegretti, Marcello, Garcia, Cristiana Couto, Martins, Marco Aurélio, Teixeira, Mauro Martins, Russo, Remo Castro
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 02.10.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Increased IL-8 levels and neutrophil accumulation in the airways are common features found in patients affected by pulmonary diseases such as Asthma, Idiopathic Pulmonary Fibrosis, Influenza-A infection and COPD. Chronic neutrophilic inflammation is usually corticosteroid insensitive and may be relevant in the progression of those diseases. To explore the role of Ladarixin, a dual CXCR1/2 antagonist, in several mouse models of airway inflammation with a significant neutrophilic component. Ladarixin was able to reduce the acute and chronic neutrophilic influx, also attenuating the Th2 eosinophil-dominated airway inflammation, tissue remodeling and airway hyperresponsiveness. Correspondingly, Ladarixin decreased bleomycin-induced neutrophilic inflammation and collagen deposition, as well as attenuated the corticosteroid resistant Th17 neutrophil-dominated airway inflammation and hyperresponsiveness, restoring corticosteroid sensitivity. Finally, Ladarixin reduced neutrophilic airway inflammation during cigarette smoke-induced corticosteroid resistant exacerbation of Influenza-A infection, improving lung function and mice survival. CXCR1/2 antagonist Ladarixin offers a new strategy for therapeutic treatment of acute and chronic neutrophilic airway inflammation, even in the context of corticosteroid-insensitivity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Diana Boraschi, Istituto di biochimica delle proteine (IBP), Italy
This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology
These authors have contributed equally to this work
Reviewed by: Cheol-Heui Yun, Seoul National University, South Korea; Raffaella Bonecchi, Humanitas University, Italy
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2020.566953